A Study to Define the ECG Effects of Lixivaptan Compared to Placebo and Moxifloxacin in Healthy Adult Men and Women: A Thorough ECG Study

Phase 1 Completed 298 enrolled CardioKine Inc. Biogen · collab Cardiokine Biopharma, LLC · collab

RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a Phase 1, double-blind, randomized, repeat-dose, single -dite, 4-arm parallel group study to define the ECG effect of lixivaptan using a therapeutic and supratherapeutic dose compared to placebo and moxifloxacin (a positive control in healthy adult men and women.

Timeline

Start: 2008-05
Primary completion: 2008-09
Completion: 2008-10

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Lixivaptan	Small molecule	—	—
Comparator	Moxifloxacin	Small molecule	—	—

Indications

No indication recorded.